Next Article in Journal
Reagent Tracker Dyes Permit Quality Control for Verifying Plating Accuracy in ELISPOT Tests
Next Article in Special Issue
Human-Induced Pluripotent Stem Cell Technology and Cardiomyocyte Generation: Progress and Clinical Applications
Previous Article in Journal
Intra- and Intercellular Quality Control Mechanisms of Mitochondria
Previous Article in Special Issue
Application of Induced Pluripotent Stem Cell Technology to the Study of Hematological Diseases
Open AccessFeature PaperReview

Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside

1
North-Western Tuscany Blood Bank, Pisa University Hospital, via Paradisa 2, 56124 Pisa, Italy
2
ADIENNE, via Zurigo 46, 6900 Lugano, Switzerland
*
Authors to whom correspondence should be addressed.
Received: 25 October 2017 / Revised: 20 December 2017 / Accepted: 23 December 2017 / Published: 27 December 2017
(This article belongs to the Special Issue Ten Years of iPSCs: Current Status and Future Perspectives)
Red blood cells and platelets are anucleate blood components indispensable for oxygen delivery and hemostasis, respectively. Derivation of these blood elements from induced pluripotent stem (iPS) cells has the potential to develop blood donor-independent and genetic manipulation-prone products to complement or replace current transfusion banking, also minimizing the risk of alloimmunization. While the production of erythrocytes from iPS cells has challenges to overcome, such as differentiation into adult-type phenotype that functions properly after transfusion, platelet products are qualitatively and quantitatively approaching a clinically-applicable level owing to advances in expandable megakaryocyte (MK) lines, platelet-producing bioreactors, and novel reagents. Guidelines that assure the quality of iPS cells-derived blood products for clinical application represent a novel challenge for regulatory agencies. Considering the minimal risk of tumorigenicity and the expected significant demand of such products, ex vivo production of iPS-derived blood components can pave the way for iPS translation into the clinic. View Full-Text
Keywords: iPS cells; transfusion; red blood cells; platelets iPS cells; transfusion; red blood cells; platelets
Show Figures

Figure 1

MDPI and ACS Style

Focosi, D.; Amabile, G. Induced Pluripotent Stem Cell-Derived Red Blood Cells and Platelet Concentrates: From Bench to Bedside. Cells 2018, 7, 2.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop